Trial Profile
An Open-Label, Randomized Study to Evaluate the Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis In Breast Cancer Patients Undergoing Radiation Therapy.
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs HO 0202 (Primary)
- Indications Radiodermatitis
- Focus Therapeutic Use
- Sponsors HealOr
- 21 Apr 2014 New trial record